Contact
searchSearch
HMP Global
Login

Tardive Dyskinesia News

doctor holds hand of older patient
News
Valbenazine Effective for Long-Term Treatment of TD in Older Adults, Analysis Finds
05/21/2025
Maria Mantas
A post hoc analysis found that valbenazine was safe and effective for the long-term treatment of tardive dyskinesia (TD) in adults aged 65 and older.
A post hoc analysis found that valbenazine was safe and effective for the long-term treatment of tardive dyskinesia (TD) in adults aged 65 and older.
A post hoc analysis found that...
05/21/2025
Psych Congress Network
poster presentation session at a conference
Conference Coverage
Deutetrabenazine Targets VMAT2 With Precision, Analysis Finds
05/12/2025
Jolynn Tumolo
Deutetrabenazine showed significant efficacy and high specificity in inhibiting its primary target, VMAT2,, in functional assessments of the drug’s deuterated metabolites. Findings were reported at the inaugural poster session at the NEI...
Deutetrabenazine showed significant efficacy and high specificity in inhibiting its primary target, VMAT2,, in functional assessments of the drug’s deuterated metabolites. Findings were reported at the inaugural poster session at the NEI...
Deutetrabenazine showed...
05/12/2025
Psychiatry & Behavioral Health
Patient survey
News
Patient Survey Identifies Barriers to TD Treatment
11/06/2024
Jolynn Tumolo
Key barriers to tardive dyskinesia (TD) diagnosis include a lack of communication with the health care professional, lack of a physical exam, and low educational and socioeconomic status, according to a survey of adults with TD symptoms.
Key barriers to tardive dyskinesia (TD) diagnosis include a lack of communication with the health care professional, lack of a physical exam, and low educational and socioeconomic status, according to a survey of adults with TD symptoms.
Key barriers to tardive...
11/06/2024
Psych Congress Network
: FDA Approves Oral Valbenazine Granule Formulation, an Alternative Administration Option for Adults With TD
News
FDA Approves Oral Valbenazine Granule Formulation, an Alternative Administration Option for Adults With TD
05/15/2024
Evi Arthur
At the end of April, Neurocrine Biosciences, Inc. announced the approval of INGREZZA® SPRINKLE (valbenazine) capsules by the FDA. This approval provides an alternative option for patients with dysphagia or who have difficulty swallowing. 
At the end of April, Neurocrine Biosciences, Inc. announced the approval of INGREZZA® SPRINKLE (valbenazine) capsules by the FDA. This approval provides an alternative option for patients with dysphagia or who have difficulty swallowing. 
At the end of April, Neurocrine...
05/15/2024
Psych Congress Network
TD Has ‘Severe Impact’ on Patients and Caregivers
News
TD Has ‘Severe Impact’ on Patients and Caregivers
05/10/2024
Evi Arthur
Tardive dyskinesia (TD) was found to have a “severe impact” on the lives of both patients and their caregivers across physical, psychological, and social domains. Results from the survey-based study were published in the Journal of Patient...
Tardive dyskinesia (TD) was found to have a “severe impact” on the lives of both patients and their caregivers across physical, psychological, and social domains. Results from the survey-based study were published in the Journal of Patient...
Tardive dyskinesia (TD) was...
05/10/2024
Psych Congress Network
Geriatric Patient with son in long term care setting
News
High Comorbidity, Polypharmacy Burden in Patients With Tardive Dyskinesia in LTC Settings
05/07/2024
Jolynn Tumolo
Patients with tardive dyskinesia (TD) in long-term care settings have a high comorbidity and polypharmacy burden, with half taking medications that may worsen TD, according to a poster presentation at the APA annual meeting.
Patients with tardive dyskinesia (TD) in long-term care settings have a high comorbidity and polypharmacy burden, with half taking medications that may worsen TD, according to a poster presentation at the APA annual meeting.
Patients with tardive dyskinesia...
05/07/2024
Psych Congress Network
Elderly patient and his doctor
News
Awareness of TD Symptoms Linked With Poorer Health, Social Functioning in Patients
05/15/2023
Jolynn Tumolo
Clinician-confirmed possible tardive dyskinesia (TD) was associated with diminished wellness and social functioning in real-world patients, according to a study published online in the Journal of Patient-Reported Outcomes.
Clinician-confirmed possible tardive dyskinesia (TD) was associated with diminished wellness and social functioning in real-world patients, according to a study published online in the Journal of Patient-Reported Outcomes.
Clinician-confirmed possible...
05/15/2023
Psych Congress Network
News
Valbenazine Use for Tardive Dyskinesia in Older Adults Proves Efficacious
12/08/2021
Heather Flint
Valbenazine use for tardive dyskinesia (TD) in adults aged 65 and older has been deemed efficacious with comparable outcomes to younger adults, according to a post hoc analysis.
Valbenazine use for tardive dyskinesia (TD) in adults aged 65 and older has been deemed efficacious with comparable outcomes to younger adults, according to a post hoc analysis.
Valbenazine use for tardive...
12/08/2021
Psych Congress Network
News
Deutetrabenazine is Beneficial for Long-Term Tardive Dyskinesia Treatment
12/03/2021
Meagan Thistle
Deutetrabenazine may provide long-term treatment benefits to patients with tardive dyskinesia (TD), according to a post hoc analysis presented in a poster at Psych Congress 2021.
Deutetrabenazine may provide long-term treatment benefits to patients with tardive dyskinesia (TD), according to a post hoc analysis presented in a poster at Psych Congress 2021.
Deutetrabenazine may provide...
12/03/2021
Psych Congress Network
News
Individual Titration of Deutetrabenazine Beneficial for Patients With Tardive Dyskinesia
11/17/2021
Erin McGuinness
Response-driven titration of deutetrabenazine is beneficial for patients with tardive dyskinesia (TD), according to new findings.
Response-driven titration of deutetrabenazine is beneficial for patients with tardive dyskinesia (TD), according to new findings.
Response-driven titration of...
11/17/2021
Psych Congress Network

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

andrew and julie
Rapid Refresh
Navigating Bipolar Disorder Treatment: Exploring the Role of Second-Generation Antipsychotics
04/11/2024

Featuring Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN

Featuring Andrew Penn, MS, PMHNP...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and...
04/11/2024
Psych Congress NP Institute
Amber Hoberg
Rapid Refresh
Long-Acting Injectables for Adolescents With Schizophrenia and Schizoaffective Disorder
04/10/2024
Amber Hoberg, MSN, APRN, PMHNP-BC
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC,...
04/10/2024
Psych Congress NP Institute
Hoberg and Matthews
Clinical Pearls
Tolerability Testing in Long-Acting Injectable Prescriptions
04/03/2024
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for...
04/03/2024
Psych Congress NP Institute

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use